A STAT3-decoy oligonucleotide induces cell death in a human colorectal carcinoma cell line by blocking nuclear transfer of STAT3 and STAT3-bound NF-κB

BMC Cell Biology

Volumn 12, Issue , 2011, Pages

  Souissi, Inès ^a,b   Najjar, Imen ^a,e   Ah Koon, Laurent ^a,b   Schischmanoff, Pierre O ^a,b,c   Lesage, Denis ^a,b   Le Coquil, Stéphanie ^a,b   Roger, Claudine ^c   Dusanter Fourt, Isabelle ^a,e   Varin Blank, Nadine ^a,b   Cao, An ^b   Metelev, Valeri ^d   Baran Marszak, Fanny ^a,b,c   Fagard, Remi ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ PARIS 13   (France)

^c AVICENNE HOSPITAL   (France)

^d MOSCOW STATE UNIVERSITY   (Russian Federation)

^e INSTITUT COCHIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; KARYOPHERIN; LEPTOMYCIN B; OLIGONUCLEOTIDE; RECOMBINANT PROTEIN; SMALL INTERFERING RNA; STAT3 PROTEIN; VANADIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL SURVIVAL; COLORECTAL CARCINOMA; COMPLEX FORMATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION REGULATION; GENE MUTATION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOPRECIPITATION; NUCLEAR LOCALIZATION SIGNAL; PROMOTER REGION; PROTEIN DNA BINDING; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TRANSCRIPTION TERMINATION; ACTIVE TRANSPORT; COLORECTAL TUMOR; GENETICS; METABOLISM; NUCLEOLUS; PATHOPHYSIOLOGY; PROTEIN BINDING; TUMOR CELL LINE;

ACTIVE TRANSPORT, CELL NUCLEUS; CELL DEATH; CELL LINE, TUMOR; CELL NUCLEOLUS; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; NF-KAPPA B; OLIGONUCLEOTIDES; PROTEIN BINDING; STAT3 TRANSCRIPTION FACTOR;

EID: 79953856965     PISSN: None     EISSN: 14712121     Source Type: Journal    
DOI: 10.1186/1471-2121-12-14     Document Type: Article

References (68)

1. Schindler C, Levy DE, Decker T. JAK-STAT signaling: from interferons to cytokines. J Biol Chem 2007, 282(28):20059-20063. 10.1074/jbc.R700016200, 17502367.
2. Silva CM. Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene 2004, 23(48):8017-8023. 10.1038/sj.onc.1208159, 15489919.
3. Vinkemeier U. Getting the message across, STAT! Design principles of a molecular signaling circuit. J Cell Biol 2004, 167(2):197-201. 10.1083/jcb.200407163, 2172545, 15504906.
4. Gorlich D. Transport into and out of the cell nucleus. Embo J 1998, 17(10):2721-2727. 10.1093/emboj/17.10.2721, 1170612, 9582265.
5. Ma J, Zhang T, Novotny-Diermayr V, Tan AL, Cao X. A novel sequence in the coiled-coil domain of Stat3 essential for its nuclear translocation. J Biol Chem 2003, 278(31):29252-29260. 10.1074/jbc.M304196200, 12746441.
6. Frank DA. STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett 2007, 251(2):199-210. 10.1016/j.canlet.2006.10.017, 17129668.
7. ten Hoeve J, de Jesus Ibarra-Sanchez M, Fu Y, Zhu W, Tremblay M, David M, Shuai K. Identification of a nuclear Stat1 protein tyrosine phosphatase. Mol Cell Biol 2002, 22(16):5662-5668. 10.1128/MCB.22.16.5662-5668.2002, 133976, 12138178.
8. Bhattacharya S, Schindler C. Regulation of Stat3 nuclear export. J Clin Invest 2003, 111(4):553-559. 151917, 12588893.
9. Bromberg JF. Activation of STAT proteins and growth control. Bioessays 2001, 23(2):161-169. 10.1002/1521-1878(200102)23:2<161::AID-BIES1023>3.0.CO;2-0, 11169589.
10. Bromberg J. Stat proteins and oncogenesis. J Clin Invest 2002, 109(9):1139-1142. 150969, 11994401.
11. Al Zaid Siddiquee K, Turkson J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res 2008, 18(2):254-267. 10.1038/cr.2008.18, 2610254, 18227858.
12. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE. Stat3 as an oncogene. Cell 1999, 98(3):295-303. 10.1016/S0092-8674(00)81959-5, 10458605.
13. Takeda K, Noguchi K, Shi W, Tanaka T, Matsumoto M, Yoshida N, Kishimoto T, Akira S. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci USA 1997, 94(8):3801-3804. 10.1073/pnas.94.8.3801, 20521, 9108058.
14. Schlessinger K, Levy DE. Malignant transformation but not normal cell growth depends on signal transducer and activator of transcription 3. Cancer Res 2005, 65(13):5828-5834. 10.1158/0008-5472.CAN-05-0317, 2100417, 15994959.
15. Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 2008, 269(2):199-225. 10.1016/j.canlet.2008.03.009, 18479807.
16. Schust J, Sperl B, Hollis A, Mayer TU, Berg T. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol 2006, 13(11):1235-1242. 10.1016/j.chembiol.2006.09.018, 17114005.
17. Tadlaoui Hbibi A, Laguillier C, Souissi I, Lesage D, Le Coquil S, Cao A, Metelev V, Baran-Marszak F, Fagard R. Efficient killing of SW480 colon carcinoma cells by a STAT3 hairpin decoy oligodeoxynucleotide. Interference with interferon gamma-STAT1-mediated killing. FEBS Journal 2009, 276:2505-2515. 10.1111/j.1742-4658.2009.06975.x, 19476491.
18. Tomita N, Ogihara T, Morishita R. Transcription factors as molecular targets: molecular mechanisms of decoy ODN and their design. Curr Drug Targets 2003, 4(8):603-608. 10.2174/1389450033490803, 14577649.
19. Yue P, Turkson J. Targeting STAT3 in cancer: how successful are we?. Expert Opin Investig Drugs 2009, 18(1):45-56. 10.1517/13543780802565791, 2610472, 19053881.
20. Son G, Iimuro Y, Seki E, Hirano T, Kaneda Y, Fujimoto J. Selective inactivation of NF-kappaB in the liver using NF-kappaB decoy suppresses CCl4-induced liver injury and fibrosis. Am J Physiol Gastrointest Liver Physiol 2007, 293(3):G631-639. 10.1152/ajpgi.00185.2007, 17640975.
21. Laguillier C, Hbibi AT, Baran-Marszak F, Metelev V, Cao A, Cymbalista F, Bogdanov A, Fagard R. Cell death in NF-kappaB-dependent tumour cell lines as a result of NF-kappaB trapping by linker-modified hairpin decoy oligonucleotide. FEBS Lett 2007, 581(6):1143-1150. 10.1016/j.febslet.2007.02.024, 17328896.
22. Leong PL, Andrews GA, Johnson DE, Dyer KF, Xi S, Mai JC, Robbins PD, Gadiparthi S, Burke NA, Watkins SF, et al. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci USA 2003, 100(7):4138-4143. 10.1073/pnas.0534764100, 153061, 12640143.
23. Aggarwal BB, Sethi G, Ahn KS, Sandur SK, Pandey MK, Kunnumakkara AB, Sung B, Ichikawa H. Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann N Y Acad Sci 2006, 1091:151-169. 10.1196/annals.1378.063, 17341611.
24. Sun X, Zhang J, Wang L, Tian Z. Growth inhibition of human hepatocellular carcinoma cells by blocking STAT3 activation with decoy-ODN. Cancer Letters 2008, 262(2):201-213. 10.1016/j.canlet.2007.12.009, 18248786.
25. Xi S, Gooding WE, Grandis JR. In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy. Oncogene 2005, 24(6):970-979. 10.1038/sj.onc.1208316, 15592503.
26. Ehret GB, Reichenbach P, Schindler U, Horvath CM, Fritz S, Nabholz M, Bucher P. DNA binding specificity of different STAT proteins. Comparison of in vitro specificity with natural target sites. J Biol Chem 2001, 276(9):6675-6688. 10.1074/jbc.M001748200, 11053426.
27. Tomita T, Takano H, Tomita N, Morishita R, Kaneko M, Shi K, Takahi K, Nakase T, Kaneda Y, Yoshikawa H, et al. Transcription factor decoy for NFkappaB inhibits cytokine and adhesion molecule expressions in synovial cells derived from rheumatoid arthritis. Rheumatology (Oxford) 2000, 39(7):749-757. 10.1093/rheumatology/39.7.749, 10908694.
28. Park YG, Nesterova M, Agrawal S, Cho-Chung YS. Dual blockade of cyclic AMP response element- (CRE) and AP-1-directed transcription by CRE-transcription factor decoy oligonucleotide. gene-specific inhibition of tumor growth. J Biol Chem 1999, 274(3):1573-1580. 10.1074/jbc.274.3.1573, 9880535.
29. Bene A, Kurten RC, Chambers TC. Subcellular localization as a limiting factor for utilization of decoy oligonucleotides. Nucleic Acids Res 2004, 32(19):e142. 10.1093/nar/gnh139, 528816, 15498923.
30. Sakaguchi M, Nukui T, Sonegawa H, Murata H, Futami J, Yamada H, Huh NH. Targeted disruption of transcriptional regulatory function of p53 by a novel efficient method for introducing a decoy oligonucleotide into nuclei. Nucleic Acids Res 2005, 33(9):e88. 10.1093/nar/gni088, 1140756, 15920103.
31. Herrmann A, Vogt M, Monnigmann M, Clahsen T, Sommer U, Haan S, Poli V, Heinrich PC, Muller-Newen G. Nucleocytoplasmic shuttling of persistently activated STAT3. J Cell Sci 2007, 120(Pt 18):3249-3261. 10.1242/jcs.03482, 17726064.
32. Liu L, McBride KM, Reich NC. STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-alpha3. Proc Natl Acad Sci USA 2005, 102(23):8150-8155. 10.1073/pnas.0501643102, 1149424, 15919823.
33. Meyer T, Vinkemeier U. STAT nuclear translocation: potential for pharmacological intervention. Expert Opin Ther Targets 2007, 11(10):1355-1365. 10.1517/14728222.11.10.1355, 17907964.
34. Lee TL, Yeh J, Friedman J, Yan B, Yang X, Yeh NT, Van Waes C, Chen Z. A signal network involving coactivated NF-kappaB and STAT3 and altered p53 modulates BAX/BCL-XL expression and promotes cell survival of head and neck squamous cell carcinomas. Int J Cancer 2008, 122(9):1987-1998. 10.1002/ijc.23324, 18172861.
35. Grivennikov SI, Karin M. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 2010, 21(1):11-19. 10.1016/j.cytogfr.2009.11.005, 2834864, 20018552.
36. Horvath CM, Wen Z, Darnell JE. A STAT protein domain that determines DNA sequence recognition suggests a novel DNA-binding domain. Genes Dev 1995, 9(8):984-994. 10.1101/gad.9.8.984, 7774815.
37. Najjar I, Deglesne PA, Schischmanoff PO, Fabre EE, Boisson-Dupuis S, Nimmerjahn F, Bornkamm GW, Dusanter-Fourt I, Fagard R. STAT1-dependent IgG cell-surface expression in a human B cell line derived from a STAT1-deficient patient. J Leukoc Biol 2010,
38. Fan Y, Zhang YL, Wu Y, Zhang W, Wang YH, Cheng ZM, Li H. Inhibition of signal transducer and activator of transcription 3 expression by RNA interference suppresses invasion through inducing anoikis in human colon cancer cells. World J Gastroenterol 2008, 14(3):428-434. 10.3748/wjg.14.428, 2679132, 18200666.
39. Wagner BJ, Hayes TE, Hoban CJ, Cochran BH. The SIF binding element confers sis/PDGF inducibility onto the c-fos promoter. EMBO J 1990, 9(13):4477-4484. 552240, 2176154.
40. Reynier P, Briane D, Cao A, Lievre N, Naejus R, Bissieres P, Salzmann JL, Taillandier E. In vitro and in vivo transfection of melanoma cells B16-F10 mediated by cholesterol-based cationic liposomes. J Drug Target 2002, 10(7):557-566. 10.1080/1061186021000038049, 12683723.
41. Lin Q, Lai R, Chirieac LR, Li C, Thomazy VA, Grammatikakis I, Rassidakis GZ, Zhang W, Fujio Y, Kunisada K, et al. Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am J Pathol 2005, 167(4):969-980. 10.1016/S0002-9440(10)61187-X, 1603671, 16192633.
42. Evans MK, Yu CR, Lohani A, Mahdi RM, Liu X, Trzeciak AR, Egwuagu CE. Expression of SOCS1 and SOCS3 genes is differentially regulated in breast cancer cells in response to proinflammatory cytokine and growth factor signals. Oncogene 2007, 26(13):1941-1948. 10.1038/sj.onc.1209993, 17001312.
43. Gu TL, Goss VL, Reeves C, Popova L, Nardone J, Macneill J, Walters DK, Wang Y, Rush J, Comb MJ, et al. Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemia. Blood 2006, 108(13):4202-4204. 10.1182/blood-2006-06-026666, 16946300.
44. Shim SH, Sung MW, Park SW, Heo DS. Absence of STAT1 disturbs the anticancer effect induced by STAT3 inhibition in head and neck carcinoma cell lines. Int J Mol Med 2009, 23(6):805-810.
45. Lee KY, Anderson E, Madani K, Rosen GD. Loss of STAT1 expression confers resistance to IFN-gamma-induced apoptosis in ME180 cells. FEBS Lett 1999, 459(3):323-326. 10.1016/S0014-5793(99)01283-1, 10526158.
46. Thomas M, Finnegan CE, Rogers KM, Purcell JW, Trimble A, Johnston PG, Boland MP. STAT1: a modulator of chemotherapy-induced apoptosis. Cancer Res 2004, 64(22):8357-8364. 10.1158/0008-5472.CAN-04-1864, 15548705.
47. Meyer T, Hendry L, Begitt A, John S, Vinkemeier U. A single residue modulates tyrosine dephosphorylation, oligomerization, and nuclear accumulation of stat transcription factors. J Biol Chem 2004, 279(18):18998-19007. 10.1074/jbc.M400766200, 15010467.
48. Kudo N, Wolff B, Sekimoto T, Schreiner EP, Yoneda Y, Yanagida M, Horinouchi S, Yoshida M. Leptomycin B inhibition of signal-mediated nuclear export by direct binding to CRM1. Exp Cell Res 1998, 242(2):540-547. 10.1006/excr.1998.4136, 9683540.
49. Bollrath J, Greten FR. IKK/NF-kappaB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis. EMBO Rep 2009, 10(12):1314-1319. 10.1038/embor.2009.243, 2799209, 19893576.
50. Fletcher S, Turkson J, Gunning PT. Molecular approaches towards the inhibition of the signal transducer and activator of transcription 3 (Stat3) protein. ChemMedChem 2008, 3(8):1159-1168. 10.1002/cmdc.200800123, 2603136, 18683176.
51. Jing N, Tweardy DJ. Targeting Stat3 in cancer therapy. Anticancer Drugs 2005, 16(6):601-607. 10.1097/00001813-200507000-00002, 15930886.
52. Reich NC, Liu L. Tracking STAT nuclear traffic. Nat Rev Immunol 2006, 6(8):602-612. 10.1038/nri1885, 16868551.
53. Ma J, Cao X. Regulation of Stat3 nuclear import by importin alpha5 and importin alpha7 via two different functional sequence elements. Cell Signal 2006, 18(8):1117-1126. 10.1016/j.cellsig.2005.06.016, 16298512.
54. Nardozzi J, Wenta N, Yasuhara N, Vinkemeier U, Cingolani G. Molecular basis for the recognition of phosphorylated STAT1 by importin alpha5. J Mol Biol 2010, 402(1):83-100. 10.1016/j.jmb.2010.07.013, 20643137.
55. Pranada AL, Metz S, Herrmann A, Heinrich PC, Muller-Newen G. Real time analysis of STAT3 nucleocytoplasmic shuttling. J Biol Chem 2004, 279(15):15114-15123. 10.1074/jbc.M312530200, 14701810.
56. Marg A, Shan Y, Meyer T, Meissner T, Brandenburg M, Vinkemeier U. Nucleocytoplasmic shuttling by nucleoporins Nup153 and Nup214 and CRM1-dependent nuclear export control the subcellular distribution of latent Stat1. J Cell Biol 2004, 165(6):823-833. 10.1083/jcb.200403057, 2172394, 15210729.
57. Yang J, Liao X, Agarwal MK, Barnes L, Auron PE, Stark GR. Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev 2007, 21(11):1396-1408. 10.1101/gad.1553707, 1877751, 17510282.
58. Yang J, Stark GR. Roles of unphosphorylated STATs in signaling. Cell Res 2008, 18(4):443-451. 10.1038/cr.2008.41, 18364677.
59. Kumar A, Commane M, Flickinger TW, Horvath CM, Stark GR. Defective TNF-alpha-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases. Science 1997, 278(5343):1630-1632. 10.1126/science.278.5343.1630, 9374464.
60. Najjar I, Fagard R. STAT1 and pathogens, not a friendly relationship. Biochimie 2010, 92:425-444. 10.1016/j.biochi.2010.02.009, 20159032.
61. Schindler C. STATs as activators of apoptosis. Trends Cell Biol 1998, 8(3):97-98. 10.1016/S0962-8924(98)01233-1, 9695817.
62. Wall L, Burke F, Smyth JF, Balkwill F. The anti-proliferative activity of interferon-gamma on ovarian cancer: in vitro and in vivo. Gynecol Oncol 2003, 88(1 Pt 2):S149-151. 10.1006/gyno.2002.6707, 12586108.
63. Labeur M, Refojo D, Wolfel B, Stalla J, Vargas V, Theodoropoulou M, Buchfelder M, Paez-Pereda M, Arzt E, Stalla GK. Interferon-gamma inhibits cellular proliferation and ACTH production in corticotroph tumor cells through a novel janus kinases-signal transducer and activator of transcription 1/nuclear factor-kappa B inhibitory signaling pathway. J Endocrinol 2008, 199(2):177-189. 10.1677/JOE-08-0011, 18715881.
64. Wagner AH, Wittjen I, Stojanovic T, Middel P, Meingassner JG, Hecker M. Signal transducer and activator of transcription 1 decoy oligodeoxynucleotide suppression of contact hypersensitivity. J Allergy Clin Immunol 2008, 121(1):158-165. e155, 10.1016/j.jaci.2007.09.015, 17981315.
65. Bromberg JF, Horvath CM, Wen Z, Schreiber RD, Darnell JE. Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc Natl Acad Sci USA 1996, 93(15):7673-7678. 10.1073/pnas.93.15.7673, 38805, 8755534.
66. Regis G, Pensa S, Boselli D, Novelli F, Poli V. Ups and downs: The STAT1:STAT3 seesaw of Interferon and gp130 receptor signalling. Semin Cell Dev Biol 2008,
67. Sen M, Tosca PJ, Zwayer C, Ryan MJ, Johnson JD, Knostman KA, Giclas PC, Peggins JO, Tomaszewski JE, McMurray TP, et al. Lack of toxicity of a STAT3 decoy oligonucleotide. Cancer Chemother Pharmacol 2009, 63(6):983-995. 10.1007/s00280-008-0823-6, 18766340.
68. Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z, Forman S, Jove R, Pardoll DM, Yu H. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 2009, 15(4):283-293. 10.1016/j.ccr.2009.02.015, 2777654, 19345327.